A Study of TNFerade™ Biologic With Concomitant Radiotherapy, Fluorouracil, and Hydroxyurea (TNF-FHX) in Patients With Head and Neck Cancer

Head and Neck Cancer Clinical Trial

Official title:

A Phase I/II Safety, Tolerability, and "Proof of Concept" Study of TNFerade™ Biologic in Combination With Concomitant Radiotherapy, Fluorouracil, and Hydroxyurea (TNF-FHX) for Patients With Unresectable Recurrent Head and Neck Cancer

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00496535
• Other study ID #: GV-001.011
• Secondary ID: GV-001.011 (TNF-
• Status: Completed
• Phase: Phase 1/Phase 2
• First received: July 2, 2007
• Last updated: February 22, 2012

Study information

• Verified date: May 2011
• Source: GenVec
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Food and Drug Administration
• Study type: Interventional

Clinical Trial Summary

The primary objective of the first phase is to determine the safety, the maximum tolerated dose (MTD) and dose-limiting toxicity of TNFerade in combination with the previously studied combination of Fluorouracil (5FU), Hydroxyurea (HU) and standard daily radiotherapy in patients with recurrent head and neck cancer (RHNC). All chemoradiotherapy is administered on a "week-on/week-off" schedule. The primary objective of the second phase II is to determine the locoregional control rate at 24 months.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 0
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Head and neck cancer

• Patients must have a locoregional tumor amenable to reirradiation with curative intent.

• disease, or the majority of disease, should be accessible to injection via direct intratumoral injection

• Life expectancy of greater than 12 weeks

• Age > 18 years

• ECOG performance status 0-1

Exclusion Criteria:

• Metastatic disease

• History of malignancy (other than head and neck cancer) in the last 2 years except carcinoma in situ of the cervix or bladder, non-melanomatous skin cancer, or localized early stage prostate cancer, with patients continually disease free, or cancers that are not felt to influence treatment for head and neck cancer and life expectancy of patient

• Patients may not be receiving any other investigational agents currently or within the 4 weeks prior to study Day 1

• Active infection of any type

• Chronic treatment for greater than 6 months with steroids

• Pregnant or lactating women

• Patients with known history of cerebral vascular disease; stroke or TIA within the last 6 months

• Patients with history of documented thrombosis (PE or DVT), or known coagulopathy or thrombophilia, or evidence of DVT / thromboembolic event upon enrollment

• Patients receiving hormone replacement therapy or hormonal contraceptives within two weeks of day 1

• Patients who have undergone surgery within the last 1 month prior to day 1

• Patients with active carotid artery involvement or status post carotid artery graft / stenting

Study Design

Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

• Head and Neck Cancer
• Head and Neck Neoplasms

Intervention

Drug:
• TNFerade biologic

Locations

Country	Name	City	State
United States	University of Chicago	Chicago	Illinois

Sponsors (1)

Lead Sponsor	Collaborator
GenVec

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	locoregional control at 24 months
Secondary	Locoregional control at 3, 6 and 12 months, as well as tumor response rate, progression-free survival at 3, 6, 12 and 24 months, and the rate of metastases at 3, 6, 12 and 24 months will also be assessed.